AbbVie to acquire Allergan in transformative move

25 Jun 2019

Transaction will create a leading biopharmaceutical company with approximately $48 billion in combined 2019 revenue.

AbbVie and Allergan have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion.

AbbVie to acquire Allergan in transformative move

"This is a transformational transaction for both companies and achieves unique and complementary strategic objectives," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "The combination of AbbVie and Allergan increases our ability to continue to deliver on our mission to patients and shareholders. With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie's business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future."

Strategic Rationale

  • New growth platforms and leadership positions to diversify and expand revenue base: The combined company will consist of several attractive franchises with leadership positions across immunology, hematologic oncology, medical aesthetics, neuroscience, women's health, eye care and virology. Allergan's product portfolio will be enhanced by AbbVie's commercial strength, expertise and international infrastructure.
  • Immediate scale and enhanced profitability for AbbVie's growth platform: AbbVie's enhanced growth platform, comprised of growing and durable franchises across highly-attractive therapeutic areas, is expected to grow at a high-single digit annual growth rate well into the next decade, from more than $30 billion in 2020.
  • Financially attractive with immediate EPS accretion: This transaction is expected to be 10% accretive to adjusted earnings per share over the first full year following the close of the transaction, with peak accretion of greater than 20%.1 ROIC is expected to exceed AbbVie's cost of capital within the first full year.
  • Significant cash flow generation: The success and scale of the combined commercial business ensures funding capacity and flexibility for simultaneous robust pipeline investment, debt reduction and capital return to shareholders. The combined companies generated $19 billion in operating cash flow in 2018.
  • "This acquisition creates compelling value for Allergan's stakeholders, including our customers, patients and shareholders. With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone," said Brent Saunders, chairman and chief executive officer, Allergan. "Our fast-growing therapeutic areas, including our world-class medical aesthetics, eye care, CNS and gastrointestinal businesses, will enhance AbbVie's strong growth platform and create substantial value for shareholders of both companies."

    Read More

    Related news

    Funding to accelerate delivery of Univercells' vaccine portfolio

    Funding to accelerate delivery of Univercells' vaccine portfolio

    11 Oct 2019

    European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

    Read more 
    Industrial-scale manufacture of therapeutic exosomes

    Industrial-scale manufacture of therapeutic exosomes

    10 Oct 2019

    Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

    Read more 
    Janssen opens new biomanufacturing building in Ireland

    Janssen opens new biomanufacturing building in Ireland

    8 Oct 2019

    Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

    Read more 
    BASF and Biomillenia join forces in microbiome research to promote healthy skin

    BASF and Biomillenia join forces in microbiome research to promote healthy skin

    7 Oct 2019

    Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

    Read more 
    Allergan expands Refresh eye treatment portfolio

    Allergan expands Refresh eye treatment portfolio

    7 Oct 2019

    A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

    Read more 
    BASF strengthens biotechnology footprint to enter natural F&F ingredients market

    BASF strengthens biotechnology footprint to enter natural F&F ingredients market

    3 Oct 2019

    Market entrance with biotech-based natural vanillin, valencene and nootkatone.

    Read more 
    Unidose device approved for Tosymra sumatriptan spray

    Unidose device approved for Tosymra sumatriptan spray

    3 Oct 2019

    Provides migraine sufferers with a convenient, patient-friendly delivery approach.

    Read more 
    One-stop-platform for plant-based nutraceuticals

    One-stop-platform for plant-based nutraceuticals

    2 Oct 2019

    In 2020, nutra brands will look to ensure they have plant-based options across all product classes with many actively looking to move entire portfolios plant-based.

    Read more 
    BASF's new bioactive ingredient the wellness elixir for healthy skin

    BASF's new bioactive ingredient the wellness elixir for healthy skin

    1 Oct 2019

    The active ingredient is a 100% natural extract from the chaga mushroom, obtained using an innovative eco-friendly technology: subcritical water extraction.

    Read more 
    Arctoris secures funding to advance novel robotic drug discovery platform

    Arctoris secures funding to advance novel robotic drug discovery platform

    1 Oct 2019

    Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

    Read more